Home › NDC Lookup › RxCUI directory › RxCUI 1806878

Crofelemer 125 MG Delayed Release Oral Tablet [Mytesi] — RxCUI 1806878

RxNorm drug concept · Semantic branded drug
RxCUI 1806878 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1806878
Official nameCrofelemer 125 MG Delayed Release Oral Tablet [Mytesi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMytesi 125 MG Delayed Release Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)301 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Crofelemer: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No — Mytesi is specifically for diarrhea that is NOT caused by an infection, in adults with HIV/AIDS who are on antiretroviral therapy. If your diarrhea is from a virus, bacteria,...
  • What exactly is Mytesi for — can I take it for any stomach bug?
  • Based on studies, Mytesi did not have a meaningful interaction with common HIV drugs like nelfinavir or zidovudine. A small reduction in lamivudine levels was seen, but it wasn't c...
  • Will this medicine interfere with my HIV medications?
📖 Read our full Crofelemer guide →

🕸️ Concept Web — How Crofelemer 125 MG Delayed Release Oral Tablet [M... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Crofelemer 125 MG Delayed Release Oral Tablet [Mytesi] RxCUI 1806878

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Crofelemer 1364449
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mytesi 1806873
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Crofelemer Delayed Release Oral Tablet 1364453
    • Crofelemer Oral Product 1364451
    • Crofelemer Pill 1364452
    • Crofelemer Delayed Release Oral Tablet [Mytesi] 1806875
    • Mytesi Oral Product 1806876
    • Mytesi Pill 1806877
    • Delayed Release Oral Tablet 10312
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Crofelemer 125 MG [Mytesi] SBDC · 1806874
  • Crofelemer Delayed Release Oral Tablet [Mytesi] SBDF · 1806875
  • Mytesi Oral Product SBDG · 1806876
  • Mytesi Pill SBDG · 1806877
  • Mytesi BN · 1806873

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1806878 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70564-0802-60 60 TABLET, COATED in 1 BOTTLE (70564-802-60) MYTESI Napo Pharmaceuticals, Inc. 2016-08-01
Observed labelers: Napo Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.